Company Profile
Petros Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- PTPI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (-51.47%)
Close
Last updated: October 1, 2026
—
Market cap
Why the stock is moving
As of Oct 1, 2026, PTPI closed down 51.5% at $0.0033. No new same-company headline was identified in the current news window.
Company overview
Rx-to-OTC Technology Developer
Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use. The company has exited its former commercial pharmaceutical and men's-health device businesses.
Software-as-a-Service Platform
The planned platform is intended to help pharmaceutical companies design and operate consumer-facing processes required for prescription-to-over-the-counter switches. Potential functions include education, self-selection, eligibility logic, and commercialization support.
Consumer Decision Interface
Petros is also developing a potential Software as a Medical Device component that would guide consumers through appropriate self-selection or deselection. The interface is intended to reduce subjectivity through clinically established decision logic.
ACNU Regulatory Framework
The strategy is aligned with the FDA's framework for nonprescription drug products with an additional condition for nonprescription use. Under this model, technology can help consumers use a medicine safely when the drug label alone is insufficient.
Discontinued Legacy Operations
Petros no longer commercializes STENDRA and has assigned the assets of its former vacuum-erection-device businesses to a third party. The company therefore operates as an early-stage technology developer rather than a current product marketer.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Petros Pharmaceuticals (PTPI)?
Petros Pharmaceuticals (PTPI) most recently closed at 0.00 USD, a -51.47% move versus the previous session.
What does Petros Pharmaceuticals do?
Rx-to-OTC Technology Developer Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use. The company has exited its former commercial pharmaceutical and men's-health device businesses. Software-as-a-Service Platform The planned platform is intended to help pharmaceutical companies design and...
On which exchange is PTPI stock listed?
Petros Pharmaceuticals (PTPI) is associated with NASDAQ, United States, Biopharma.
What is Rx-to-OTC?
Rx-to-OTC Technology Developer Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use.
Which conditions is Petros Pharmaceuticals targeting with Rx-to-OTC?
Rx-to-OTC Technology Developer Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use. The company has exited its former commercial pharmaceutical and men's-health device businesses. Software-as-a-Service Platform The planned platform is intended to help pharmaceutical companies design and...
What is Technology?
Rx-to-OTC Technology Developer Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use.
What is Developer?
Rx-to-OTC Technology Developer Petros Pharmaceuticals is developing technology intended to help prescription medicines transition to nonprescription use.